Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
The present invention relates to compositions that comprise immediate release and extended release guaifenesin, extended release phenylephrine and immediate and extended release dextromethorphan. The present invention also includes methods for using these compositions for treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.
1 . A composition comprising guaifenesin, phenylephrine and dextromethorphan, wherein said composition is administrable to a patient.
2 . The composition of claim 1 , wherein said composition is substantially free of other added active ingredients.
3 . The composition of claim 2 , wherein said other added active ingredient is another antitussive.
4 . The composition of claim 3 , wherein said another antitussive comprises one or more selected from the group consisting of codeine, codeine phosphate, codeine sulfate, morphine, morphine sulfate, hydrocodone, hydromorphone hydrochloride, levorphanol tartrate, oxycodone hydrochloride, oxymorphone hydrochloride, methadone hydrochloride, apomorphine hydrochloride, beechwood creosote, benzonatate, camphor ethanedisulfonate, diphenhydramine, diphenhydramine hydrochloride, dextromethorphan, dextromethorphan hydrobromide, chlophendianol hydrochloride, carbetapentane citrate, caramiphen edisylate, noscapine, noscapine hydrochloride, and menthol.
5 . The composition of claim 2 , wherein said other added active ingredient is a decongestant.
6 . The composition of claim 5 , wherein said decongestant comprises a nasal decongestant.
7 . The composition of claim 6 , wherein said nasal decongestant comprises one or more selected from the group consisting of ephedrine, ephedrine sulfate, ephedrine hydrochloride, psuedoephedrine hydrochloride, epinephrine bitartrate, hydroxyamphetamine hydrobromide, propylhexedrine, phenylpropanolamine hydrochloride, mephentermine sulfate, methoxamine hydrochloride, naphazoline hydrochloride, oxymetalozine hydrochloride, tetrahydrozoline hydrochloride and xylometazoline hydrochloride.
8 . The composition of claim 2 , wherein said other added active ingredient is another opioid analgesic.
9 . The composition of claim 8 , wherein said another opioid analgesic comprises one or more selected from the group consisting of codeine, morphine, hydromorphone, oxymorphone, hydrocodone, levorphanol, fentanyl, propoxyphene, diphenoxylate, meperidine, methadone, and oxycodone.
10 . The composition of claim 2 , wherein said other added active ingredient is another expectorant.
11 . The composition of claim 10 , wherein said another expectorant comprises one or more selected from the group consisting of ammonium chloride, ammonium carbonate, acetylcysteine, antimony potassium tartrate, glycerin, potassium iodide, sodium citrate, terpin hydrate and tolu balsam.
12 . The composition of claim 1 , wherein said composition is in a dosage form that is solid.
13 . The composition of claim 12 , wherein dosage form is a caplet.
14 . The composition of claim 12 , wherein the guaifenesin comprises an immediate release guaifenesin and an extended release variant form of guaifenesin.
15 . The composition of claim 14 , wherein the extended release variant form of guaifenesin is at least one selected from the group consisting of guaiacolsulfonate and guaifenesin tannate.
16 . The composition of claim 14 , wherein the immediate release guaifenesin and the extended release variant form of guaifenesin are formulated in an immediate release matrix.
17 . The composition of claim 14 , wherein the extended release variant form of guaifenesin is formulated in an immediate release matrix and the dosage form is coated with an immediate release coating comprising guaifenesin.
18 . The composition of claim 12 , wherein the dextromethorphan comprises an immediate release dextromethorphan and an extended release variant form of dextromethorphan.
19 . The composition of claim 18 , wherein the extended release variant form is dextromethorphan tannate.
20 . The composition of claim 18 , wherein the immediate release dextromethorphan and the extended release variant form of dextromethorphan is formulated in an immediate release matrix.
21 . The composition of claim 18 , wherein the extended release variant form of dextromethorphan is formulated in an immediate release matrix and the dosage form is coated with an immediate release coating comprising dextromethorphan.
22 . The composition of claim 12 , wherein phenylephrine comprises an extended release variant form of phenylephrine.
23 . The composition of claim 22 , wherein the extended release variant form of phenylephrine is phenylephrine tannate.
24 . The composition of claim 23 , wherein the extended release variant form of phenylephrine is formulated in an immediate release matrix.
25 . The composition of claim 12 , wherein the dosage form is formulated so that phenylephrine is released in a controlled release manner, and guaifenesin and dextromethorphan are released in an immediate release and a controlled release manner.
26 . The composition of claim 25 , wherein substantially all of the drugs are released from the dosage form by about 12 hours after ingestion by a patient.
27 . The composition of claim 25 , wherein guaifenesin, phenylephrine and dextromethorphan are formulated in an immediate release matrix and the resulting dosage form is coated with a delayed release coating.
28 . The composition of claim 27 , wherein the dosage form is additionally coated with an exterior coating of an immediate release coating comprising at least one selected from the group consisting of guaifenesin and dextromethorphan.
29 . The composition of claim 27 , which comprises particles comprising at least one selected from the group consisting of guaifenesin, phenylephrine and dextromethorphan in an immediate release matrix with a delayed release coating.
30 . A composition, in which the particles of claim 29 are enclosed in a capsule or compressed into tablet.
31 . The composition of claim 29 , wherein the delayed release coating is of varied compositions and thicknesses.
32 . The composition of claim 29 , further comprising particles of an immediate release matrix comprising at least one selected from the group consisting of guaifenesin and dextromethorphan without a delay release coating.
33 . The composition of claim 29 , further comprising particles having an exterior coating of an immediate release coating comprising at least one selected from the group consisting of guaifenesin and dextromethorphan.
34 . The composition of claim 25 , wherein at least part of the guaifenesin, phenylephrine and/or dextromethorphan are formulated in an extended release matrix.
35 . The composition of claim 34 , wherein the dosage form is coated with an immediate release matrix or coating comprising at least one from the group of guaifenesin and dextromethorphan.
36 . The composition of claim 1 , wherein said composition comprises about 100 mg per dose to about 300 mg per dose immediate release guaifenesin.
37 . The composition of claim 1 , wherein said composition comprises about 200 mg per dose to about 600 mg per dose extended release guaifenesin.
38 . The composition of claim 1 , wherein said composition comprises about 4.5 mg per dose to about 13.5 mg per dose extended release phenylephrine.
39 . The composition of claim 1 , wherein said composition comprises about 4 mg per dose to about 12 mg per dose immediate release dextromethorphan.
40 . The composition of claim 1 , wherein said composition comprises about 7.5 mg per dose to about 22.5 mg per dose extended release dextromethorphan.
41 . The composition of claim 1 , wherein said composition comprises about 150 mg per dose to about 250 mg per dose immediate release guaifenesin.
42 . The composition of claim 1 , wherein said composition comprises about 300 mg per dose to about 500 mg per dose extended release guaifenesin.
43 . The composition of claim 1 , wherein said composition comprises about 6.75 mg per dose to about 11.25 mg per dose extended release phenylephrine.
44 . The composition of claim 1 , wherein said composition comprises about 10 mg per dose to about 6 mg per dose immediate release dextromethorphan.
45 . The composition of claim 1 , wherein said composition comprises about 11.25 mg per dose to about 18.75 mg per dose extended release dextromethorphan.
46 . The composition of claim 1 , wherein said composition comprises about 180 mg per dose to about 220 mg per dose immediate release guaifenesin.
47 . The composition of claim 1 , wherein said composition comprises about 360 mg per dose to about 440 mg per dose extended release guaifenesin.
48 . The composition of claim 1 , wherein said composition comprises about 8.1 mg per dose to about 9.9 mg per dose extended release phenylephrine.
49 . The composition of claim 1 , wherein said composition comprises about 7.2 mg per dose to about 8.8 mg per dose immediate release dextromethorphan.
50 . The composition of claim 1 , wherein said composition comprises about 13.5 mg per dose to about 16.5 mg per dose extended release dextromethorphan.
51 . The composition of claim 1 , wherein said composition comprises about 190 mg per dose to about 210 mg per dose immediate release guaifenesin.
52 . The composition of claim 1 , wherein said composition comprises about 380 mg per dose to about 420 mg per dose extended release guaifenesin.
53 . The composition of claim 1 , wherein said composition comprises about 8.55 mg per dose to about 9.45 mg per dose extended release phenylephrine.
54 . The composition of claim 1 , wherein said composition comprises about 7.6 mg per dose to about 8.4 mg per dose immediate release dextromethorphan.
55 . The composition of claim 1 , wherein said composition comprises about 14.25 mg per dose to about 15.75 mg per dose extended release dextromethorphan.
56 . The composition of claim 1 , wherein said composition comprises about 190 mg per dose to about 210 mg per dose immediate release guaifenesin; about 380 mg per dose to about 420 mg per dose extended release guaifenesin; about 8.55 mg per dose to about 9.45 mg per dose extended release phenylephrine; about 7.6 mg per dose to about 8.4 mg per dose immediate release dextromethorphan; and about 14.25 mg per dose to about 15.75 mg per dose extended release dextromethorphan.
57 . The composition of claim 1 , wherein said composition comprises about 200 mg per dose immediate release guaifenesin.
58 . The composition of claim 1 , wherein said composition comprises about 400 mg per dose extended release guaifenesin.
59 . The composition of claim 1 , wherein said composition comprises about 9 mg per dose extended release phenylephrine.
60 . The composition of claim 1 , wherein said composition comprises about 8 mg per dose immediate release dextromethorphan.
61 . The composition of claim 1 , wherein said composition comprises about 15 mg per dose extended release dextromethorphan.
62 . The composition of claim 1 , wherein said composition comprises about 200 mg per dose immediate release guaifenesin; about 400 mg per dose extended release guaifenesin; about 9 mg per dose extended release phenylephrine; about 8 mg per dose immediate release dextromethorphan; and about 15 mg per dose extended release dextromethorphan.
63 . A method comprising administering to a patient a composition comprising the composition of claim 1 .
64 . The method of claim 63 , wherein the composition is administered to the patient orally.
65 . The method of claim 63 wherein the composition is administered to the patient at a frequency selected from the group consisting of once a day, twice a day, three times a day and four times a day.
66 . The method of claim 63 , wherein the composition is administered to the patient in a dose unit selected from the group consisting of 0.5, 1, 1.5, 2, 2.5 and 3 dosage forms.
67 . The method of claim 63 , wherein the patient is suffering from at least one condition selected from the group consisting of coughing, sneezing, rhinorrhea, nasal obstruction, nasal congestion, nasal pruritus, rhinorrhea, allergies, allergic vasomotor rhinitis (hay fever), seasonal allergic vasomotor rhinitis, perennial allergic vasomotor rhinitis, bronchography, bronchoscopy, a respiratory disease, a cold, acute bronchitis, chronic bronchitis, asthmatic bronchitis, bronchiectasis, pneumonia, lung tuberculosis, silicosis, silicotuberculosis, pulmonary cancer, upper respiratory inflammation, pharyngitis, laryngitis, nasal catarrh, asthma, bronchial asthma, infantile asthma, pulmonary emphysema, pneumoconiosis, pulmonary fibrosis, pulmonary silicosis, pulmonary suppuration, pleuritis, tonsillitis, cough hives, and whooping cough.